Cyclin-dependent kinase 1 and survivin as potential therapeutic targets against nasal natural killer/T-cell lymphoma.
Nagato T, Ueda S, Takahara M, Kishibe K, Komabayashi Y, Kumai T, Ohara K, Hirata-Nozaki Y, Harabuchi S, Hayashi R, Ohkuri T, Bernasconi M, Nadal D, Kobayashi H, Harabuchi Y.
Nagato T, et al.
Lab Invest. 2019 May;99(5):612-624. doi: 10.1038/s41374-018-0182-9. Epub 2019 Jan 21.
Lab Invest. 2019.
PMID: 30664711
Free article.